Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2016

View Archived Issues

Two-antibody cocktail MIL77E protects primates from Ebola virus

NEOMED Institute announces partnership opportunities

EM Imaging and Mauna Kea enter clinical molecular imaging research collaboration

Researchers present novel murine models to study Zika virus

FDA grants orphan drug designation to ANAVEX 3-71 for frontotemporal dementia

Conference round-up: Biomarker studies from the USCAP Annual Meeting

MRC Technology and IPS-CAS enter antibody research agreement

FDA grants priority review to atezolizumab BLA in NSCLC

Bayer Schering Pharma discloses factor XIa kallikrein B inhibitors

Merck & Co. patents prolyl hydroxylase inhibitors

Shifa Biomedical reports endothelial lipase inhibitors

MedImmune reports antibodies linked to dimeric pyrrolobenzodiazepine

Helmsley Charitable Trust funds research into cell-based therapies for type 1 diabetes

Human Vaccines Project announces Mesa Consortium

Pritumumab receives FDA orphan drug designation for the treatment of pancreatic cancer

Somatostatin-dopamine chimeric compound demonstrates preclinical efficacy for acromegaly

Merck KGaA announces CE Mark approval for OncoBEAM RAS CRC test

FDA advisory committee set to review rociletinib NDA

MSD K.K. and Taiho sign copromotion agreement for pembrolizumab in Japan

Kyoto University and Sumitomo Dainippon Pharma launch second stage of DSK Project

4D pharma acquires Spanish company Instituto Biomar

FDA approves BromSite to prevent pain and treat inflammation following cataract surgery

EMA committee recommends that Alprolix maintains orphan drug designation

Addex Therapeutics announces results from dipraglurant clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...